Abnormal neuronal differentiation and mitochondrial dysfunction in hair follicle-derived induced pluripotent stem cells of schizophrenia patients

Molecular Psychiatry

Volumn 18, Issue 10, 2013, Pages 1067-1076

  Robicsek, O ^a   Karry, R ^a   Petit, I ^b,c   Salman Kesner, N ^b   Muller F J ^d   Klein, E ^a   Aberdam, D ^b,c   Ben Shachar, D ^a  

^a RAMBAM MEDICAL CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d Zentrum fur Integrative Psychiatrie   (Germany)

Author keywords

iPSC; mitochondria; neural differentiation; schizophrenia

Indexed keywords

BETA TUBULIN; BETA3 TUBULIN; NESTIN; TRANSCRIPTION FACTOR PAX6; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ARTICLE; CASE REPORT; CELL LINEAGE; CELL MATURATION; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOPAMINERGIC NERVE CELL; GLUTAMATERGIC NERVE CELL; HAIR FOLLICLE; HUMAN; HUMAN CELL; HYPOTHESIS; KERATINOCYTE; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL RESPIRATION; NERVE CELL; NERVE CELL DIFFERENTIATION; NERVOUS SYSTEM DEVELOPMENT; NEURAL STEM CELL; NUCLEAR REPROGRAMMING; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; SCHIZOPHRENIA;

ANTIGENS, DIFFERENTIATION; CELL LINEAGE; CELLS, CULTURED; DOPAMINE AGENTS; ECTODERM; EXCITATORY AMINO ACID AGENTS; GENE EXPRESSION REGULATION; HAIR FOLLICLE; HUMANS; INDUCED PLURIPOTENT STEM CELLS; KERATINOCYTES; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; MODELS, NEUROLOGICAL; NERVE TISSUE PROTEINS; NEUROGENESIS; NEURONS; OXYGEN CONSUMPTION; RNA, MESSENGER; SCHIZOPHRENIA, PARANOID;

EID: 84884669370     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2013.67     Document Type: Article

References (64)

1. Brown AS. The environment and susceptibility to schizophrenia. Prog Neurobiol 2011; 93: 23-58.
2. Rapoport JL, Giedd JN, Gogtay N. Neurodevelopmental model of schizophrenia: update 2012. Mol Psychiatry 2012; 17: 1228-1238.
3. Faludi G, Mirnics K. Synaptic changes in the brain of subjects with schizophrenia. Int J Dev Neurosci 2011; 29: 305-309.
4. Bauer M, Praschak-Rieder N, Kasper S, Willeit M. Is dopamine neurotransmission altered in prodromal schizophrenia? A review of the evidence. Curr Pharm Des 2012; 18: 1568-1579.
5. Fusar-Poli P, Howes OD, Allen P, Broome M, Valli I, Asselin MC et al. Abnormal prefrontal activation directly related to pre-synaptic striatal dopamine dysfunction in people at clinical high risk for psychosis. Mol Psychiatry 2011; 16: 67-75.
6. Belforte JE, Zsiros V, Sklar ER, Jiang Z, Yu G, Li Y et al. Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes. Nat Neurosci 2010; 13: 76-83.
7. Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III-the final common pathway. Schizophr Bull 2009; 35: 549-562.
8. Finlay JM. Mesoprefrontal dopamine neurons and schizophrenia: role of developmental abnormalities. Schizophr Bull 2001; 27: 431-442. (Pubitemid 33081695)
9. Laruelle M, Kegeles LS, Abi-Dargham A. Glutamate, dopamine, and schizophrenia. Ann N Y Acad Sci 2003; 1003: 138-158.
10. Li Z, Okamoto K, Hayashi Y, Sheng M. The importance of dendritic mitochondria in the morphogenesis and plasticity of spines and synapses. Cell 2004; 119: 873-887. (Pubitemid 40017692)
11. Sequeira A, Martin MV, Rollins B, Moon EA, Bunney WE, Macciardi F et al. Mitochondrial mutations and polymorphisms in psychiatric disorders. Front Genet 2012; 3: 103.
12. Manji H, Kato T, Di Prospero NA, Ness S, Beal MF, Krams M et al. Impaired mitochondrial function in psychiatric disorders. Nat Rev Neurosci 2012; 13: 293-307.
13. Marazziti D, Baroni S, Picchetti M, Landi P, Silvestri S, Vatteroni E et al. Psychiatric disorders and mitochondrial dysfunctions. Eur Rev Med Pharmacol Sci 2012; 16: 270-275.
14. Rosenfeld M, Brenner-Lavie H, Ari SG, Kavushansky A, Ben-Shachar D. Perturbation in mitochondrial network dynamics and in complex I dependent cellular respiration in schizophrenia. Biol Psychiatry 2011; 69: 980-988.
15. Ishihara N, Nomura M, Jofuku A, Kato H, Suzuki SO, Masuda K et al. Mitochondrial fission factor Drp1 is essential for embryonic development and synapse formation in mice. Nat Cell Biol 2009; 11: 958-966.
16. Greenwood SM, Mizielinska SM, Frenguelli BG, Harvey J, Connolly CN. Mitochondrial dysfunction and dendritic beading during neuronal toxicity. J Biol Chem 2007; 282: 26235-26244. (Pubitemid 47443787)
17. White RJ, Reynolds IJ. Mitochondrial depolarization in glutamate-stimulated neurons: an early signal specific to excitotoxin exposure. J Neurosci 1996; 16: 5688-5697. (Pubitemid 26293392)
18. Garcia O, Almeida A, Massieu L, Bolanos JP. Increased mitochondrial respiration maintains the mitochondrial membrane potential and promotes survival of cerebellar neurons in an endogenous model of glutamate receptor activation. J Neurochem 2005; 92: 183-190. (Pubitemid 40193520)
19. Ben-Shachar D. The interplay between mitochondrial complex I, dopamine and Sp1 in schizophrenia. J Neural Transm 2009; 116: 1383-1396.
20. Brenner-Lavie H, Klein E, Ben-Shachar D. Mitochondrial complex I as a novel target for intraneuronal DA: modulation of respiration in intact cells. Biochem Pharmacol 2009; 78: 85-95.
21. Ben-Shachar D, Zuk R, Gazawi H, Ljubuncic P. Dopamine toxicity involves mitochondrial complex I inhibition: implications to dopamine-related neuropsychiatric disorders. Biochem Pharmacol 2004; 67: 1965-1974. (Pubitemid 38591384)
22. Ben-Shachar D. Mitochondrial dysfunction in schizophrenia: a possible linkage to dopamine. J Neurochem 2002; 83: 1241-1251. (Pubitemid 35477464)
23. Brennand KJ, Simone A, Jou J, Gelboin-Burkhart C, Tran N, Sangar S et al. Modelling schizophrenia using human induced pluripotent stem cells. Nature 2011; 473: 221-225.
24. Brennand KJ, Gage FH. Concise review: the promise of human induced pluripotent stem cell-based studies of schizophrenia. Stem Cells 2011; 29: 1915-1922.
25. Matigian N, Abrahamsen G, Sutharsan R, Cook AL, Vitale AM, Nouwens A et al. Disease-specific, neurosphere-derived cells as models for brain disorders. Dis Model Mech 2010; 3: 785-798.
26. Pedrosa E, Sandler V, Shah A, Carroll R, Chang C, Rockowitz S et al. Development of patient-specific neurons in schizophrenia using induced pluripotent stem cells. J Neurogenet 2011; 25: 88-103.
27. Brennand KJ, Simone A, Tran N, Gage FH. Modeling psychiatric disorders at the cellular and network levels. Mol Psychiatry 2012; 17: 1239-1253.
28. Paulsen BD, Maciel RD, Galina A, da Silveira MS, Souza CD, Drummond H et al. Altered oxygen metabolism associated to neurogenesis of induced pluripotent stem cells derived from a schizophrenic patient. Cell Transplant 2011; 21: 1547-1559.
29. da Silveira Paulsen B, Souza da Silveira M, Galina A, Kastrup Rehen S. Pluripotent stem cells as a model to study oxygen metabolism in neurogenesis and neurodevelopmental disorders. Arch Biochem Biophys 2013; 534: 3-10.
30. Mortimer AM. Symptom rating scales and outcome in schizophrenia. Br J Psychiatry Suppl 2007; 50: s7-14. (Pubitemid 47204549)
31. Petit I, Kesner NS, Karry R, Robicsek O, Aberdam E, Muller FJ et al. Induced pluripotent stem cells from hair follicles as a cellular model for neurodevelopmental disorders. Stem Cell Res 2012; 8: 134-140.
32. Somers A, Jean J-C, Sommer CA, Omari A, Ford CC, Mills JA et al. Generation of transgene-free lung disease-specific human induced pluripotent stem cells using a single excisable lentiviral stem cell cassette. Stem Cells 2010; 28: 1728-1740.
33. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126: 663-676. (Pubitemid 44233629)
34. Muller FJ, Schuldt BM, Williams R, Mason D, Altun G, Papapetrou EP et al. A bioinformatic assay for pluripotency in human cells. Nat Methods 2011; 8: 315-317.
35. Williams R, Schuldt B, Muller FJ. A guide to stem cell identification: progress and challenges in system-wide predictive testing with complex biomarkers. BioEssays 2011; 33: 880-890.
36. Zeng H, Guo M, Martins-Taylor K, Wang X, Zhang Z, Park JW et al. Specification of region-specific neurons including forebrain glutamatergic neurons from human induced pluripotent stem cells. PLoS One 2010; 5: e11853.
37. Chambers SM, Fasano CA, Papapetrou EP, Tomishima M, Sadelain M, Studer L. Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat Biotechnol 2009; 27: 275-280.
38. Yaniv SP, Lucki A, Klein E, Ben-Shachar D. Dexamethasone enhances the norepinephrine-induced ERK/MAPK intracellular pathway possibly via dysregulation of the alpha2-adrenergic receptor: implications for antidepressant drug mechanism of action. Eur J Cell Biol 2010; 89: 712-722.
39. Fekkes D. State-of-the-art of high-performance liquid chromatographic analysis of amino acids in physiological samples. J Chromatogr B 1996; 682: 3-22. (Pubitemid 26228279)
40. Brenner-Lavie H, Klein E, Zuk R, Gazawi H, Ljubuncic P, Ben-Shachar D. Dopamine modulates mitochondrial function in viable SH-SY5Y cells possibly via its interaction with complex I: relevance to dopamine pathology in schizophrenia. Biochim Biophys Acta 2008; 1777: 173-185. (Pubitemid 351162862)
41. Romero-Ramos M, Vourc'h P, Young HE, Lucas PA, Wu Y, Chivatakarn O et al. Neuronal differentiation of stem cells isolated from adult muscle. J Neurosci Res 2002; 69: 894-907. (Pubitemid 34984706)
42. Nazor KL, Altun G, Lynch C, Tran H, Harness JV, Slavin I et al. Recurrent variations in DNA methylation in human pluripotent stem cells and their differentiated derivatives. Cell Stem Cell 2012; 10: 620-634.
43. Shalom-Feuerstein R, Serror L, De La Forest Divonne S, Petit I, Aberdam E, Camargo L et al. Pluripotent stem cell model reveals essential roles for miR-450b-5p and miR-184 in embryonic corneal lineage specification. Stem Cells 2012; 30: 898-909.
44. Kleinman JE, Law AJ, Lipska BK, Hyde TM, Ellis JK, Harrison PJ et al. Genetic neuropathology of schizophrenia: new approaches to an old question and new uses for postmortem human brains. Biol Psychiatry 2011; 69: 140-145.
45. Ugrumov MV. Non-dopaminergic neurons partly expressing dopaminergic phenotype: distribution in the brain, development and functional significance. J Chem Neuroanat 2009; 38: 241-256.
46. Bjö rklund A, Dunnett SB. Dopamine neuron systems in the brain: an update. Trends Neurosci 2007; 30: 194-202. (Pubitemid 46654237)
47. Kapur S, Remington G. Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol Psychiatry 2001; 50: 873-883. (Pubitemid 34020700)
48. Schmitt A, Hasan A, Gruber O, Falkai P. Schizophrenia as a disorder of disconnectivity. Eur Arch Psychiatry Clin Neurosci 2011; 261(Suppl 2): S150-S154.
49. Dames P, Puff R, Weise M, Parhofer KG, Goke B, Gotz M et al. Relative roles of the different Pax6 domains for pancreatic alpha cell development. BMC Dev Biol 2010; 10: 39.
50. Guinez C, Morelle W, Michalski JC, Lefebvre T. O-GlcNAc glycosylation: a signal for the nuclear transport of cytosolic proteins? Int J Biochem Cell Biol 2005; 37: 765-774. (Pubitemid 40202998)
51. Lesaffre B, Joliot A, Prochiantz A, Volovitch M. Direct non-cell autonomous Pax6 activity regulates eye development in the zebrafish. Neural Dev 2007; 2: 2.
52. Krupkova O Jr, Loja T, Zambo I, Veselska R. Nestin expression in human tumors and tumor cell lines. Neoplasma 2010; 57: 291-298.
53. Gonzalez-Garza MT, Martinez HR, Caro-Osorio E, Cruz-Vega DE, Hernandez-Torre M, Moreno-Cuevas JE. Differentiation of CD133+ stem cells from amyotrophic lateral sclerosis patients into preneuron cells. Stem Cells Transl Med 2013; 2: 129-135.
54. Hashimoto K, Engberg G, Shimizu E, Nordin C, Lindstrom LH, Iyo M. Elevated glutamine/glutamate ratio in cerebrospinal fluid of first episode and drug naive schizophrenic patients. BMC Psychiatry 2005; 5: 6.
55. Eisenhofer G, Kopin IJ, Goldstein DS. Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol Rev 2004; 56: 331-349. (Pubitemid 39096594)
56. Johri A, Beal MF. Mitochondrial dysfunction in neurodegenerative diseases. J Pharmacol Exp Therap 2012; 342: 619-630.
57. Trushina E, Nemutlu E, Zhang S, Christensen T, Camp J, Mesa J et al. Defects in mitochondrial dynamics and metabolomic signatures of evolving energetic stress in mouse models of familial Alzheimer's disease. PLoS One 2012; 7: e32737.
58. Solá S, Morgado AL, Rodrigues CMP. Death receptors and mitochondria: two prime triggers of neural apoptosis and differentiation. Biochim Biophys Acta (BBA) 2013; 1830: 2160-2166.
59. Ben-Shachar D, Karry R. Neuroanatomical pattern of mitochondrial complex I pathology varies between schizophrenia, bipolar disorder and major depression. PLoS One 2008; 3: e3676.
60. Perrier AL, Tabar V, Barberi T, Rubio ME, Bruses J, Topf N et al. Derivation of midbrain dopamine neurons from human embryonic stem cells. Proc Natl Acad Sci USA 2004; 101: 12543-12548. (Pubitemid 39122060)
61. Jonas P. The time course of signaling at central glutamatergic synapses. News Physiol Sci 2000; 15: 83-89.
62. Diamond JS, Jahr CE. Transporters buffer synaptically released glutamate on a submillisecond time scale. J Neurosci 1997; 17: 4672-4687. (Pubitemid 27246925)
63. Llado J, Haenggeli C, Maragakis NJ, Snyder EY, Rothstein JD. Neural stem cells protect against glutamate-induced excitotoxicity and promote survival of injured motor neurons through the secretion of neurotrophic factors. Mol Cell Neurosci 2004; 27: 322-331. (Pubitemid 39433844)
64. Brazel CY, Nunez JL, Yang Z, Levison SW. Glutamate enhances survival and proliferation of neural progenitors derived from the subventricular zone. Neuroscience 2005; 131: 55-65. (Pubitemid 40170488)